As we countdown to World Alzheimer’s Day on 21 September, important conversations around the role of technological innovation will be vital in transforming brain health and improving the lives of those living with dementia, both now and in the future.
After years of dedicated research, scientists are on the verge of exciting major diagnostic advances in AD that could potentially transform the lives and prospects of hundreds of millions of people worldwide.
A new generation of highly effective tests – based on biomarkers, digital health technology and ground-breaking psychometric analysis – is poised to resolve the long-standing difficulties in AD diagnosis, potentially making it as commonplace as the current universal tests for cancer screening. With this leap in progress comes the prospect of much earlier intervention, potentially more effective treatment from novel therapeutics and maybe even prevention altogether.
Read the full article here
Professor Bjoern Schelter is CEO of GT Diagnostics Ltd, part of the Genting TauRx Diagnostic Centre Sdn Bhd, founded as a joint venture between Genting Bhd and TauRx Therapeutics Ltd.
